

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignina 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/846,456	05/02/2001	Marie-Francoise Rosier-Montus	3806.0505	1457		
22852 7	7590 07/16/2003					
•	FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER EXAMINER					
LLP 1300 I STREE		OF	LEFFERS JR,	GERALD G		
WASHINGIO	N, DC 20005		ART UNIT	PAPER NUMBER		
		ابيا	1636	12		
		\	DATE MAILED: 07/16/2003	ı		
		PROPERTY OF TRADEMAN				

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEVED

JUL 1 8 2003

FINNEGAN, HENDERSON, FARABOW, GARRETT AND DUNNER, LLP

Docketed 07-18-03 Atterney CPE SPO 19TR
Case 03806. 0505
Due Date 08-15-03 W 1++
Action SEQ LST DUE
By IMS

PTO-90C (Rev. 07-01)

JUL 2 1 REC'D

OIP	Application No.	Applicant(s)				
Notice to Comply AUG 1	(4 2003 <u>2</u>	AL.				
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	4 2003 Examiner	Art Unit				
NOTICE TO COMPLY MITH DECLINATION	Gerald G. Leffers Jr.	1636				
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES						
Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).						
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):						
☑ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).						
 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c). 						
 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). 						
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."						
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).						
☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).						
7. Other: Nucleic acid sequences are present in the specification for which there is no sequence identifier, no sequence in the paper copy of the sequence listing or CRF (e.g. primer sequences on pages 104 - 105)						
Applicant Must Provide: ☑ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".						
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.						
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).						
For questions regarding compliance to the	ese requirements, please c	contact:				
For Rules Interpretation, call (703) 308-42 For CRF Submission Help, call (703) 308- PatentIn Software Program Support	-4212					
Technical Assistance To Purchase Patentin Software						
PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY						

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
WWW.uspto.gov

APPLICATION NO./ FILING DATE FIRST NAMED INVENTOR / ATTORNEY DOCKET NO. PATENT IN REEXAMINATION



EXAMINER				
Gerald G. Leffers Jr.				
ART UNIT	PAPER			
1636	12			

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gerald G. Leffers Jr. whose telephone number is (703)-308-6232. The examiner can normally be reached on Monday through Friday, 9:30 am to 6:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel can be reached at (703) 305-1998. The fax number for the organization where this application or proceeding is assigned is (703) 305-1998.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to **Zeta Adams** whose telephone number is (703) 305-3291.

Gerald G. Leffers Jr., PhD.

Examiner, Art Unit 1636